These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

65 related articles for article (PubMed ID: 27201036)

  • 21. [Study on the availability and cost of medicines in the private sector in Mali].
    Maïga MD; Diawara A
    Med Trop (Mars); 2006 Dec; 66(6):565-8. PubMed ID: 17286022
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Risk-sharing agreements for innovative drugs: a new solution to old problems?
    de Pouvourville G
    Eur J Health Econ; 2006 Sep; 7(3):155-7. PubMed ID: 16912890
    [No Abstract]   [Full Text] [Related]  

  • 23. Potential Risk-Sharing Agreements for Vaccines.
    Terlinden A; Ethgen O; Demarteau N; Curran D
    Value Health; 2014 Nov; 17(7):A669-70. PubMed ID: 27202454
    [No Abstract]   [Full Text] [Related]  

  • 24. The Possibility of Initiating True Risk-Sharing Agreements in the Current Economic Situation.
    Germanenko A; Traulsen JM
    Value Health; 2014 Nov; 17(7):A449. PubMed ID: 27201227
    [No Abstract]   [Full Text] [Related]  

  • 25. Trends in cost sharing among selected high income countries--2000-2010.
    Hossein Z; Gerard A
    Health Policy; 2013 Sep; 112(1-2):35-44. PubMed ID: 23809913
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Guidance for Risk Sharing Agreements / Pay Per: Results SCHEMES FOR PHARMACEUTICALS IN CATALONIA (SPAIN).
    Mora-Ripoll R; Gilabert-Perramon A; Espinosa-Tome C; Segú L; Gasol-Boncompte M
    Value Health; 2014 Nov; 17(7):A447. PubMed ID: 27201216
    [No Abstract]   [Full Text] [Related]  

  • 27. Medicare and Medicaid programs, health care financing research and demonstration cooperative agreements and grants and availability of funds for cooperative agreements and grants--HCFA. General notice.
    Fed Regist; 1985 Jan; 50(20):4480-9. PubMed ID: 10269611
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prices & availability of common medicines at six sites in India using a standard methodology.
    Kotwani A; Ewen M; Dey D; Iyer S; Lakshmi PK; Patel A; Raman K; Singhal GL; Thawani V; Tripathi S; Laing R
    Indian J Med Res; 2007 May; 125(5):645-54. PubMed ID: 17642500
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Main challenges facing the pharmaceutical sector in Buchanan County, Virginia: a pilot study.
    Gavaza P; Yan W; Campbell J
    Rural Remote Health; 2012 Oct; 12(4):2125. PubMed ID: 23140593
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Physicians' strike for internationally comparable salaries. Analysis of the opposition to the German public sector collective agreements and the new pay and conditions agreements for physicians].
    Lindhorst E
    Unfallchirurg; 2007 Jun; 110(6):581-7. PubMed ID: 17551704
    [No Abstract]   [Full Text] [Related]  

  • 31. Ethnic differences in prevalence and determinants of mother-child bed-sharing in early childhood.
    Luijk MP; Mileva-Seitz VR; Jansen PW; van IJzendoorn MH; Jaddoe VW; Raat H; Hofman A; Verhulst FC; Tiemeier H
    Sleep Med; 2013 Nov; 14(11):1092-9. PubMed ID: 23994270
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Analysis of the pharmaceuticals market and its technological development in Turkey.
    Kisa A
    Int J Technol Assess Health Care; 2006; 22(4):537-42. PubMed ID: 16984690
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmaceutical sector in transition--a cross sectional study in Vietnam.
    Falkenberg T; Nguyen TB; Larsson M; Nguyen TD; Tomson G
    Southeast Asian J Trop Med Public Health; 2000 Sep; 31(3):590-7. PubMed ID: 11289028
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Monitoring the impacts of trade agreements on food environments.
    Friel S; Hattersley L; Snowdon W; Thow AM; Lobstein T; Sanders D; Barquera S; Mohan S; Hawkes C; Kelly B; Kumanyika S; L'Abbe M; Lee A; Ma J; Macmullan J; Monteiro C; Neal B; Rayner M; Sacks G; Swinburn B; Vandevijvere S; Walker C;
    Obes Rev; 2013 Oct; 14 Suppl 1():120-34. PubMed ID: 24074216
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Niche markets and evidence assessment in transition: a critical review of proposed drug reforms.
    Gibson SG; Lemmens T
    Med Law Rev; 2014; 22(2):200-20. PubMed ID: 24841527
    [TBL] [Abstract][Full Text] [Related]  

  • 36. NCI cooperative research and development agreements.
    Ivy SP
    Oncology (Williston Park); 2000 Dec; 14(12 Suppl 11):27-9. PubMed ID: 11204659
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rebates and spreads: pharmacy benefit management practices and corporate citizenship.
    Rentmeester CA; Garis RI
    J Health Polit Policy Law; 2008 Oct; 33(5):943-63; discussion 965-978. PubMed ID: 18818428
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of self-orientations and work-context-related variables on the well-being of public- and private-sector Turkish employees.
    Imamoğlu EO; Beydoğan B
    J Psychol; 2011; 145(4):267-96. PubMed ID: 21834322
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Applying Programme Budgeting Marginal Analysis in the health sector: 12 years of experience.
    Grocott R
    Expert Rev Pharmacoecon Outcomes Res; 2009 Apr; 9(2):181-7. PubMed ID: 19402806
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Medical research and the pharmaceutical industry. Uneasy bedfellows or a prenuptial agreement?].
    Cohen AF
    Ned Tijdschr Geneeskd; 2001 Jul; 145(30):1438-42. PubMed ID: 11503309
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.